31251-41-9Relevant articles and documents
Method for preparing anti-allergic rhinitis medicine loratadine intermediate
-
Paragraph 0056-0092, (2018/07/30)
The invention belongs to the technical field of chemical medicine preparation and particularly relates to a method for preparing an anti-allergic rhinitis medicine, namely a loratadine intermediate. According to the method, ammonium meta-tungstate is adopted as a WO3 precursor, ZrOC12*8H2O is adopted as a ZrO2 precursor, and a WO3/ZrO2 solid super-strong acid is supported by sulfamic acid graftingmodified silica gel, and then a silica gel supported solid acid is prepared. As 8-chlorine-5,6-dihydro-11H-benzo[5,6] cycloheptane[1,2-b] pyridine-11-ketone is prepared from the novel silica gel supported solid acid through catalysis, the problem of excessive wastewater is overcome, the environment protection burden is alleviated, and the reaction yield can be increased.
Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors:Design, synthesis, and biological data of inhibitors with improved physicochemical properties
Karcher, Solveigh C.,Laufer, Stefan A.
supporting information; experimental part, p. 1778 - 1782 (2010/03/01)
We recently described a promising novel class of p38 mitogen activated protein (MAP) kinase inhibitors with dibenzepinone-scaffolds. To optimize their physicochemical properties, characterized by calculated log P values and measured lipophilicity (chromatographic hydrophobicity index=CHI), we synthesized aza-analogue dibenzepinones. Here, we present the synthesis and biological data of compounds with the novel aza-dibenzepinone scaffolds. Although these aza-analogues revealed an improved aqueous solubility, introduction of nitrogen was not effective in the p38 MAPK enzyme assay.
A PROCESS FOR PREPARING BENZOCYCLOHEPTAPYRIDIN-11-ONES
-
Page 8, (2010/02/08)
A novel method for generating dianions using 3-methylpyridine-2-carboxylic acid derivatives of formula (V) or using their corresponding alkali metal salts of formula (VI), preferably from their lithium salt (Scheme 3) is described. The substituents R, R, R, R, R, R and R in Scheme 3 are defined as herein described above. Preferably the substituents are selected from one or more of hydrogen, halogen or C1-C6 alkyl groups. M is represented by any alkali metal ion, preferably lithium.